China Animal Healthcare says wholly-owned unit Shenzhou Pagina-kang Technology Co. today entered into a letter of intent with Beijing Jianxiang Hemu Biological Technology to acquire its entire assets and undertakings.

Beijing Jianxiang Hemu Biological Technology was established in 2007 and has been engaged mainly in the R&D of biological drugs and has a paid-up registered capital of RMB4 million ($0.84 million).